There are three main subtypes and they’re grouped by three genetic markers your doctor will look for on a biopsy specimen: ...

The U.S. Food and Drug Administration (FDA) has approved its Guardant360® CDx as a companion diagnostic to identify patients ...

FDA approved the monotherapy for estrogen receptor (ER)–positive and HER2-negative metastatic breast cancer. The FDA approved imlunestrant (Inluriyo; Eli Lilly and Company) for treating adults with ...

Breast cancer is a complex disease with numerous classifications. Understanding risk factors such as age, family history, genetic mutations such as breast cancer gene 1/breast cancer gene 2 ...

The regulatory approval of the oral estrogen receptor antagonist is for patients whose cancer has an ESR1 mutation and has ...

Breast cancer is a complex disease with many types. Understanding the specific type and classification of the breast cancer you have is crucial so that you can fully participate as an informed partner ...

In HR+/HER- early breast cancer, the DFS benefits of adjuvant ribociclib plus NSAI treatment compared to NSAI alone persisted even a year after treatment completion.

The study did meet the primary PFS primary end point; the median PFS for dato-DXd is 6.9 months vs 4.9 months in the ...

The evERA study showed significant PFS improvements with giredestrant plus everolimus in ER-positive, HER2-negative breast ...